ATE136901T1 - Antigen gegen diabetes - Google Patents

Antigen gegen diabetes

Info

Publication number
ATE136901T1
ATE136901T1 AT89902951T AT89902951T ATE136901T1 AT E136901 T1 ATE136901 T1 AT E136901T1 AT 89902951 T AT89902951 T AT 89902951T AT 89902951 T AT89902951 T AT 89902951T AT E136901 T1 ATE136901 T1 AT E136901T1
Authority
AT
Austria
Prior art keywords
cell
species
antigen against
against diabetes
somatic cell
Prior art date
Application number
AT89902951T
Other languages
English (en)
Inventor
Kim Sze Tan
Original Assignee
Ks Biomedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888803757A external-priority patent/GB8803757D0/en
Priority claimed from GB888803756A external-priority patent/GB8803756D0/en
Application filed by Ks Biomedix Ltd filed Critical Ks Biomedix Ltd
Application granted granted Critical
Publication of ATE136901T1 publication Critical patent/ATE136901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89902951T 1988-02-18 1989-02-15 Antigen gegen diabetes ATE136901T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888803757A GB8803757D0 (en) 1988-02-18 1988-02-18 Antigens against autoimmune diseases
GB888803756A GB8803756D0 (en) 1988-02-18 1988-02-18 Hybrid cells for producing biological products

Publications (1)

Publication Number Publication Date
ATE136901T1 true ATE136901T1 (de) 1996-05-15

Family

ID=26293506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89902951T ATE136901T1 (de) 1988-02-18 1989-02-15 Antigen gegen diabetes

Country Status (5)

Country Link
EP (1) EP0401271B1 (de)
JP (1) JPH03502795A (de)
AT (1) ATE136901T1 (de)
DE (1) DE68926294T2 (de)
WO (1) WO1989007601A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
SE9402090D0 (sv) * 1994-06-14 1994-06-14 Rudolf Valenta Recombinent molecules, proteins/polypeptides, host systems and diagnostic and therapeutic methods for atopy
AU5744800A (en) * 1999-06-16 2001-01-02 Biocrystal Limited Vaccine formulations and methods for immunizing an individual against shed antigen-specific b cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
EP0155676A3 (de) * 1984-03-19 1988-02-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Gewinnung der globulären Domäne von Basalmembrankollagen und immunologische Bestimmung von Basalmembranmaterial und Autoantikörpern
WO1987005929A1 (en) * 1986-04-01 1987-10-08 Genelabs Incorporated Immortalized cells which produce tissue-specific products
ZA874410B (en) * 1986-06-24 1988-04-27 Merrell Dow Pharma Fusion products

Also Published As

Publication number Publication date
DE68926294T2 (de) 1996-09-19
JPH03502795A (ja) 1991-06-27
EP0401271A1 (de) 1990-12-12
WO1989007601A1 (en) 1989-08-24
EP0401271B1 (de) 1996-04-17
DE68926294D1 (de) 1996-05-23

Similar Documents

Publication Publication Date Title
ATE13317T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozytantigen; antikoerper und verfahren zu seiner herstellung; diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
IL59919A0 (en) A monoclonal antibody of class lgg,its preparation and pharmaceutical compositions containing it
DK609985A (da) Adhesin-antigener, antistoffer mod disse og dna-fragmenter, som indkoder antigenerne
ES531986A0 (es) Un metodo de producir una forma geneticamente estable de vidrio cholerae
ATE13198T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellenantigen, antikoerper und verfahren.
DE69426564D1 (de) Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28
NO159882C (no) Monoklonalt antistoff.
NO159887C (no) Monoklonalt antistoff.
NO883362L (no) Fremgangsmaate for gjenanvendelse av silisiumbasismateriale anvendt for solceller.
ES497423A0 (es) Un anticuerpo monoclonico
DE68926294D1 (de) Antigen gegen diabetes
DE3854267D1 (de) HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung.
ATE109004T1 (de) Toleranzinduktion gegenüber einem fremdantigen.
ES2101694T3 (es) Expresion de edulcorantes proteinicos en levadura.
IT7967442A0 (it) Procedimento e dispositivo per la fabbricazione dei recipienti isolanti a doppia parete particolarmente di vetro
GB8823081D0 (en) Human monoclonal antibodies specifically recognizing rabies virus cells cells producing the same formulations containing the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee